Radiobiology of Stereotactic Body Radiation Therapy/Stereotactic Ablative Radiotherapy

  • Michael D. Story
  • Chaitanya Nirodi
  • Clinton Park
Part of the Medical Radiology book series (MEDRAD)


Stereotactic body radiation therapy (SBRT) or stereotactic ablative radiotherapy (SABR) is rapidly being adopted as a treatment modality, particularly for liver and lung tumors, and because of the dramatic improvements in tumor control, the use of SBRT is being directed toward other anatomical sites. The success of SBRT has been primarily technology-driven; however, application of fully potent SBRT regimes is now impeded by biological limitations. While the use of SBRT will continue to increase, there are aspects of both normal tissue and tumor response to high dose per fraction radiation exposures that require a further understanding in order to augment the technology gains as well as to minimize the potential harm done by inappropriate application of fully potent SBRT regimes. From a radiobiological perspective, there is a shift in thinking about the models used to extrapolate biological effects at high dose per fraction although the underlying mechanisms are not understood. There are also potential scheduling benefits for SBRT that can be exploited. As such, it may be appropriate to re-examine radioprotective or hypoxic cell cytotoxic agents that were either abandoned or not actively used given their considerable side effects. This may be especially true for hypoxia as the argument can be made on a mechanistic basis that SBRT is inappropriate for use with hypoxic tumors. However, we would challenge that notion. We will discuss these topics from a radiobiological perspective.


Stereotactic Body Radiation Therapy Ataxia Telangiectasia Mutate Hypoxic Tumor PARP Inhibition Synthetic Lethality 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. Abraham RT (2001) Cell cycle checkpoint signaling through the ATM and ATR kinases. Genes Dev 15:2177–2196PubMedCrossRefGoogle Scholar
  2. Abraham RT (2004) PI 3-kinase related kinases: ‘big’ players in stress-induced signaling pathways. DNA Repair (Amst) 3:883–887CrossRefGoogle Scholar
  3. Albertella MR, Loadman PM, Jones PH, Phillips RM, Rampling R, Burnet N, Alcock C, Anthoney A, Vjaters E, Dunk CR, Harris PA, Wong A, Lalani AS, Twelves CJ (2008) Hypoxia-selective targeting by the bioreductive prodrug AQ4N in patients with solid tumors: results of a phase I study. Clin Cancer Res 14:1096–1104PubMedCrossRefGoogle Scholar
  4. Anscher MS, Chen L, Rabbani Z, Kang S, Larrier N, Huang H, Samulski TV, Dewhirst MW, Brizel DM, Folz RJ, Vujaskovic Z (2005) Recent progress in defining mechanisms and potential targets for prevention of normal tissue injury after radiation therapy. Int J Radiat Oncol Biol Phys 62:255–259PubMedCrossRefGoogle Scholar
  5. Antonadou D, Petridis A, Synodinou M, Throuvalas N, Bolanos N, Veslemes M, Sagriotis A (2003a) Amifostine reduces radiochemotherapy-induced toxicities in patients with locally advanced non-small cell lung cancer. Semin Oncol 30:2–9PubMedCrossRefGoogle Scholar
  6. Antonadou D, Throuvalas N, Petridis A, Bolanos N, Sagriotis A, Synodinou M (2003b) Effect of amifostine on toxicities associated with radiochemotherapy in patients with locally advanced non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 57:402–408PubMedCrossRefGoogle Scholar
  7. Astrahan M (2008) BED calculations for fractions of very high dose: in regard to Park et al. (Int J Radiat Oncol Biol Phys 2007;69:S623–S624) Int J Radiat Oncol Biol Phys 71:963; author reply 963–964Google Scholar
  8. Begg AC, Sheldon PW, Foster JL (1974) Demonstration of radiosensitization of hypoxic cells in solid tumours by metronidazole. Br J Radiol 47:399–404PubMedCrossRefGoogle Scholar
  9. Bristow RG, Hill RP (2008) Hypoxia and metabolism. Hypoxia, DNA repair and genetic instability. Nat Rev Cancer 8:180–192PubMedCrossRefGoogle Scholar
  10. Brizel DM, Scully SP, Harrelson JM, Layfield LJ, Bean JM, Prosnitz LR, Dewhirst MW (1996) Tumor oxygenation predicts for the likelihood of distant metastases in human soft tissue sarcoma. Cancer Res 56:941–943PubMedGoogle Scholar
  11. Brown JM (1984) Clinical trials of radiosensitizers: what should we expect? Int J Radiat Oncol Biol Phys 10:425–429PubMedCrossRefGoogle Scholar
  12. Brown JM (1993) SR 4233 (tirapazamine): a new anticancer drug exploiting hypoxia in solid tumours. Br J Cancer 67:1163–1170PubMedCrossRefGoogle Scholar
  13. Bryant HE, Schultz N, Thomas HD, Parker KM, Flower D, Lopez E, Kyle S, Meuth M, Curtin NJ, Helleday T (2005) Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 434:913–917PubMedCrossRefGoogle Scholar
  14. Buentzel J, Micke O, Adamietz IA, Monnier A, Glatzel M, de Vries A (2006) Intravenous amifostine during chemoradiotherapy for head-and-neck cancer: a randomized placebo-controlled phase III study. Int J Radiat Oncol Biol Phys 64:684–691PubMedCrossRefGoogle Scholar
  15. Burma S, Chen BP, Chen DJ (2006) Role of non-homologous end joining in the repair of DNA double-strand breaks book: DNA repair, genetic instability, and cancer. DNA Repair (Amsterdam) 5:1042–1048Google Scholar
  16. Cardenas-Navia LI, Mace D, Richardson RA, Wilson DF, Shan S, Dewhirst MW (2008) The pervasive presence of fluctuating oxygenation in tumors. Cancer Res 68:5812–5819PubMedCrossRefGoogle Scholar
  17. Carlson DJ, Keall PJ, Loo BW Jr, Chen ZJ, Brown JM (2011) Hypofractionation results in reduced tumor cell kill compared to conventional fractionation for tumors with regions of hypoxia. Int J Radiat Oncol Biol Phys 79:1188–1195PubMedCrossRefGoogle Scholar
  18. Chan DA, Giaccia AJ (2007) Hypoxia, gene expression, and metastasis. Cancer Metastasis Rev 26:333–339PubMedCrossRefGoogle Scholar
  19. Chan N, Koch CJ, Bristow RG (2009) Tumor hypoxia as a modifier of DNA strand break and cross-link repair. Curr Mol Med 9:401–410PubMedCrossRefGoogle Scholar
  20. De Bock K, Mazzone M, Carmeliet P (2011) Antiangiogenic therapy, hypoxia, and metastasis: risky liaisons, or not? Nat Rev Clin Oncol 8:393–404PubMedCrossRefGoogle Scholar
  21. Delanian S, Baillet F, Huart J, Lefaix JL, Maulard C, Housset M (1994) Successful treatment of radiation-induced fibrosis using liposomal Cu/Zn superoxide dismutase: clinical trial. Radiother Oncol 32:12–20PubMedCrossRefGoogle Scholar
  22. Dorr W, Spekl K, Farrell CL (2002a) Amelioration of acute oral mucositis by keratinocyte growth factor: fractionated irradiation. Int J Radiat Oncol Biol Phys 54:245–251PubMedCrossRefGoogle Scholar
  23. Dorr W, Spekl K, Farrell CL (2002b) The effect of keratinocyte growth factor on healing of manifest radiation ulcers in mouse tongue epithelium. Cell Prolif 35(Suppl 1):86–92PubMedCrossRefGoogle Scholar
  24. Edwards RA, Witherspoon M, Wang K, Afrasiabi K, Pham T, Birnbaumer L, Lipkin SM (2009) Epigenetic repression of DNA mismatch repair by inflammation and hypoxia in inflammatory bowel disease-associated colorectal cancer. Cancer Res 69:6423–6429PubMedCrossRefGoogle Scholar
  25. Elkind MM, Sutton H (1959) X-ray damage and recovery in mammalian cells in culture. Nature 184:1293–1295PubMedCrossRefGoogle Scholar
  26. Ellis F (1971) Nominal standard dose and the ret. Br J Radiol 44:101–108PubMedCrossRefGoogle Scholar
  27. Epperly M, Bray J, Kraeger S, Zwacka R, Engelhardt J, Travis E, Greenberger J (1998) Prevention of late effects of irradiation lung damage by manganese superoxide dismutase gene therapy. Gene Ther 5:196–208PubMedCrossRefGoogle Scholar
  28. Farmer H, McCabe N, Lord CJ, Tutt AN, Johnson DA, Richardson TB, Santarosa M, Dillon KJ, Hickson I, Knights C, Martin NM, Jackson SP, Smith GC, Ashworth A (2005) Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434:917–921PubMedCrossRefGoogle Scholar
  29. Fowler JF (2008) Linear quadratics is alive and well: in regard to Park et al. (Int J Radiat Oncol Biol Phys 2008;70:847–852) Int J Radiat Oncol Biol Phys 72:957; author reply 958Google Scholar
  30. Fu XL, Huang H, Bentel G, Clough R, Jirtle RL, Kong FM, Marks LB, Anscher MS (2001) Predicting the risk of symptomatic radiation-induced lung injury using both the physical and biologic parameters V(30) and transforming growth factor beta. Int J Radiat Oncol Biol Phys 50:899–908PubMedCrossRefGoogle Scholar
  31. Fujino M, Shirato H, Onishi H, Kawamura H, Takayama K, Koto M, Onimaru R, Nagata Y, Hiraoka M (2006) Characteristics of patients who developed radiation pneumonitis requiring steroid therapy after stereotactic irradiation for lung tumors. Cancer J 12:41–46PubMedCrossRefGoogle Scholar
  32. Garcia-Barros M, Paris F, Cordon-Cardo C, Lyden D, Rafii S, Haimovitz-Friedman A, Fuks Z, Kolesnick R (2003) Tumor response to radiotherapy regulated by endothelial cell apoptosis. Science 300:1155–1159PubMedCrossRefGoogle Scholar
  33. Garcia-Barros M, Thin TH, Maj J, Cordon-Cardo C, Haimovitz-Friedman A, Fuks Z, Kolesnick R (2010) Impact of stromal sensitivity on radiation response of tumors implanted in SCID hosts revisited. Cancer Res 70:8179–8186PubMedCrossRefGoogle Scholar
  34. Gray LH, Conger AD, Ebert M, Hornsey S, Scott OC (1953) The concentration of oxygen dissolved in tissues at the time of irradiation as a factor in radiotherapy. Br J Radiol 26:638–648PubMedCrossRefGoogle Scholar
  35. Grdina DJ, Murley JS, Kataoka Y, Epperly W (2002) Relationships between cytoprotection and mutation prevention by WR-1065. Mil Med 167:51–53PubMedGoogle Scholar
  36. Grdina DJ, Murley JS, Kataoka Y, Baker KL, Kunnavakkam R, Coleman MC, Spitz DR (2009) Amifostine induces antioxidant enzymatic activities in normal tissues and a transplantable tumor that can affect radiation response. Int J Radiat Oncol Biol Phys 73:886–896PubMedCrossRefGoogle Scholar
  37. Greijer AE, van der Wall E (2004) The role of hypoxia inducible factor 1 (HIF-1) in hypoxia induced apoptosis. J Clin Pathol 57:1009–1014PubMedCrossRefGoogle Scholar
  38. Guerrero M, Li XA (2004) Extending the linear-quadratic model for large fraction doses pertinent to stereotactic radiotherapy. Phys Med Biol 49:4825–4835PubMedCrossRefGoogle Scholar
  39. Hackenbeck T, Knaup KX, Schietke R, Schodel J, Willam C, Wu X, Warnecke C, Eckardt KU, Wiesener MS (2009) HIF-1 or HIF-2 induction is sufficient to achieve cell cycle arrest in NIH3T3 mouse fibroblasts independent from hypoxia. Cell Cycle 8:1386–1395PubMedCrossRefGoogle Scholar
  40. Hammond EM, Giaccia AJ (2005) The role of p53 in hypoxia-induced apoptosis. Biochem Biophys Res Commun 331:718–725PubMedCrossRefGoogle Scholar
  41. Hammond EM, Denko NC, Dorie MJ, Abraham RT, Giaccia AJ (2002) Hypoxia links ATR and p53 through replication arrest. Mol Cell Biol 22:1834–1843PubMedCrossRefGoogle Scholar
  42. Hammond EM, Green SL, Giaccia AJ (2003) Comparison of hypoxia-induced replication arrest with hydroxyurea and aphidicolin-induced arrest. Mutat Res 532:205–213PubMedCrossRefGoogle Scholar
  43. He J, Luster TA, Thorpe PE (2007) Radiation-enhanced vascular targeting of human lung cancers in mice with a monoclonal antibody that binds anionic phospholipids. Clin Cancer Res 13:5211–5218PubMedCrossRefGoogle Scholar
  44. He J, Yin Y, Luster TA, Watkins L, Thorpe PE (2009) Antiphosphatidylserine antibody combined with irradiation damages tumor blood vessels and induces tumor immunity in a rat model of glioblastoma. Clin Cancer Res 15:6871–6880PubMedCrossRefGoogle Scholar
  45. Henk JM, Bishop K, Shepherd SF (2003) Treatment of head and neck cancer with CHART and nimorazole: phase II study. Radiother Oncol 66:65–70PubMedCrossRefGoogle Scholar
  46. Hewitt HB, Wilson CW (1959) A survival curve for mammalian leukaemia cells irradiated in vivo (implications for the treatment of mouse leukaemia by whole-body irradiation). Br J Cancer 13:69–75PubMedCrossRefGoogle Scholar
  47. Hill RP, Marie-Egyptienne DT, Hedley DW (2009) Cancer stem cells, hypoxia and metastasis. Semin Radiat Oncol 19:106–111PubMedCrossRefGoogle Scholar
  48. Hornsey S (1977) Protection by hypoxia and the effect of low oxygen tensions on radiosensitivity. Experientia Suppl 27:31–43PubMedGoogle Scholar
  49. Johnson N, Li YC, Walton ZE, Cheng KA, Li D, Rodig SJ, Moreau LA, Unitt C, Bronson RT, Thomas HD, Newell DR, D’Andrea AD, Curtin NJ, Wong KK, Shapiro GI (2011) Compromised CDK1 activity sensitizes BRCA-proficient cancers to PARP inhibition. Nat Med 17:875–882PubMedCrossRefGoogle Scholar
  50. Kang S (2003) Overexpression of extracellular superoxide dismutase protects mice against radiation-induced lung injury. Int J Radiat Biol Oncol Phys 57:1056–1066CrossRefGoogle Scholar
  51. Kataoka Y, Basic I, Perrin J, Grdina DJ (1992) Antimutagenic effects of radioprotector WR-2721 against fission-spectrum neurons and 60Co gamma-rays in mice. Int J Radiat Biol 61:387–392PubMedCrossRefGoogle Scholar
  52. Kataoka Y, Perrin J, Hunter N, Milas L, Grdina DJ (1996) Antimutagenic effects of amifostine: clinical implications. Semin Oncol 23:53–57PubMedGoogle Scholar
  53. Kavanagh BD, Newman F (2008) Toward a unified survival curve: in regard to Park et al. (IntJ Radiat Oncol Biol Phys 2008;70:847–852) and Krueger et al. (Int J Radiat Oncol Biol Phys 2007;69:1262–1271) Int J Radiat Oncol Biol Phys 71:958–959Google Scholar
  54. Kawase T, Kunieda E, Deloar HM, Seki S, Sugawara A, Tsunoo T, Ogawa EN, Ishizaka A, Kameyama K, Takeda A, Kubo A (2007) Experimental stereotactic irradiation of normal rabbit lung: computed tomographic analysis of radiation injury and the histopathological features. Radiat Med 25:453–461PubMedCrossRefGoogle Scholar
  55. Komaki R, Lee JS, Milas L, Lee HK, Fossella FV, Herbst RS, Allen PK, Liao Z, Stevens CW, Lu C, Zinner RG, Papadimitrakopoulou VA, Kies MS, Blumenschein GR Jr, Pisters KM, Glisson BS, Kurie J, Kaplan B, Garza VP, Mooring D, Tucker SL, Cox JD (2004) Effects of amifostine on acute toxicity from concurrent chemotherapy and radiotherapy for inoperable non-small-cell lung cancer: report of a randomized comparative trial. Int J Radiat Oncol Biol Phys 58:1369–1377PubMedCrossRefGoogle Scholar
  56. Koukourakis MI (2002) Hypofractionated and accelerated radiotherapy with amifostine cytoprotection (HypoARC): a new concept in radiotherapy and encouraging results in breast cancer. Semin Oncol 29:42–46PubMedCrossRefGoogle Scholar
  57. Koukourakis MI, Patlakas G, Froudarakis ME, Kyrgias G, Skarlatos J, Abatzoglou I, Bougioukas G, Bouros D (2007) Hypofractionated accelerated radiochemotherapy with cytoprotection (Chemo-HypoARC) for inoperable non-small cell lung carcinoma. Anticancer Res 27:3625–3631PubMedGoogle Scholar
  58. Li C, Jackson RM (2002) Reactive species mechanisms of cellular hypoxia-reoxygenation injury. Am J Physiol Cell Physiol 282:C227–C241PubMedGoogle Scholar
  59. Lin A, Lawrence TS (2006) An anaphylactoid reaction from amifostine. Radiother Oncol 79:352PubMedCrossRefGoogle Scholar
  60. Maj JG, Paris F, Haimovitz-Friedman A, Venkatraman E, Kolesnick R, Fuks Z (2003) Microvascular function regulates intestinal crypt response to radiation. Cancer Res 63:4338–4341PubMedGoogle Scholar
  61. Marks LB (1995) Extrapolating hypofractionated radiation schemes from radiosurgery data: regarding Hall et al., IJROBP 21:819–824; 1991 and Hall and Brenner, IJROBP 25:381–385; 1993. Int J Radiat Oncol Biol Phys 32:274–276Google Scholar
  62. McGarry RC, Papiez L, Williams M, Whitford T, Timmerman RD (2005) Stereotactic body radiation therapy of early-stage non-small-cell lung carcinoma: phase I study. Int J Radiat Oncol Biol Phys 63:1010–1015PubMedCrossRefGoogle Scholar
  63. McKenna F, Ahmad S (2009) Toward a unified survival curve: in regard to Kavanagh and Newman (Int J Radiat Oncol Biol Phys 2008;71:958–959) and Park et al. (Int J Radiat Oncol Biol Phys 2008;70:847–852) Int J Radiat Oncol Biol Phys 73:640Google Scholar
  64. Mell LK, Malik R, Komaki R, Movsas B, Swann RS, Langer C, Antonadou D, Koukourakis M, Mundt AJ (2007) Effect of amifostine on response rates in locally advanced non-small-cell lung cancer patients treated on randomized controlled trials: a meta-analysis. Int J Radiat Oncol Biol Phys 68:111–118PubMedCrossRefGoogle Scholar
  65. Moulder JE, Cohen EP (2007) Future strategies for mitigation and treatment of chronic radiation-induced normal tissue injury. Semin Radiat Oncol 17:141–148PubMedCrossRefGoogle Scholar
  66. Mueller-Klieser W, Schlenger KH, Walenta S, Gross M, Karbach U, Hoeckel M, Vaupel P (1991) Pathophysiological approaches to identifying tumor hypoxia in patients. Radiother Oncol 20(Suppl 1):21–28PubMedCrossRefGoogle Scholar
  67. Muniyappa H, Song S, Mathews CK, Das KC (2009) Reactive oxygen species-independent oxidation of thioredoxin in hypoxia: inactivation of ribonucleotide reductase and redox-mediated checkpoint control. J Biol Chem 284:17069–17081PubMedCrossRefGoogle Scholar
  68. Overgaard J (1994) Clinical evaluation of nitroimidazoles as modifiers of hypoxia in solid tumors. Oncol Res 6:509–518PubMedGoogle Scholar
  69. Overgaard J, Overgaard M, Nielsen OS, Pedersen AK, Timothy AR (1982) A comparative investigation of nimorazole and misonidazole as hypoxic radiosensitizers in a C3H mammary carcinoma in vivo. Br J Cancer 46:904–911PubMedCrossRefGoogle Scholar
  70. Overgaard J, Sand Hansen H, Lindelov B, Overgaard M, Jorgensen K, Rasmusson B, Berthelsen A (1991) Nimorazole as a hypoxic radiosensitizer in the treatment of supraglottic larynx and pharynx carcinoma. First report from the Danish Head and Neck Cancer Study (DAHANCA) protocol 5-85. Radiother Oncol 20(Suppl 1):143–149Google Scholar
  71. Overgaard J, Hansen HS, Overgaard M, Bastholt L, Berthelsen A, Specht L, Lindelov B, Jorgensen K (1998) A randomized double-blind phase III study of nimorazole as a hypoxic radiosensitizer of primary radiotherapy in supraglottic larynx and pharynx carcinoma. Results of the danish head and neck cancer study (DAHANCA) Protocol 5-85. Radiother Oncol 46:135–146PubMedCrossRefGoogle Scholar
  72. Papadopoulos KP, Goel S, Beeram M, Wong A, Desai K, Haigentz M, Milian ML, Mani S, Tolcher A, Lalani AS, Sarantopoulos J (2008) A phase 1 open-label, accelerated dose-escalation study of the hypoxia-activated prodrug AQ4N in patients with advanced malignancies. Clin Cancer Res 14:7110–7115PubMedCrossRefGoogle Scholar
  73. Papadopoulou MV, Bloomer WD (2003) NLCQ-1 (NSC 709257): exploiting hypoxia with a weak DNA-intercalating bioreductive drug. Clin Cancer Res 9:5714–5720PubMedGoogle Scholar
  74. Papadopoulou MV, Ji M, Rao MK, Bloomer WD (2001) 4-[3-(2-Nitro-1-imidazolyl)propylamino]-7-chloroquinoline hydrochloride (NLCQ-1), a novel bioreductive agent as radiosensitizer in vitro and in vivo: comparison with tirapazamine. Oncol Res 12:325–333PubMedGoogle Scholar
  75. Papadopoulou MV, Bloomer WD, Taylor AP, Hernandez M, Blumenthal RD, Hollingshead MG (2007) Advantage of combining NLCQ-1 (NSC 709257) with radiation in treatment of human head and neck xenografts. Radiat Res 168:65–71PubMedCrossRefGoogle Scholar
  76. Park C, Papiez L, Zhang S, Story M, Timmerman RD (2008) Universal survival curve and single fraction equivalent dose: useful tools in understanding potency of ablative radiotherapy. Int J Radiat Oncol Biol Phys 70:847–852PubMedCrossRefGoogle Scholar
  77. Patel AG, Sarkaria JN, Kaufmann SH (2011) Nonhomologous end joining drives poly(ADP-ribose) polymerase (PARP) inhibitor lethality in homologous recombination-deficient cells. Proc Natl Acad Sci U S A 108:3406–3411PubMedCrossRefGoogle Scholar
  78. Potten CS, O’Shea JA, Farrell CL, Rex K, Booth C (2001) The effects of repeated doses of keratinocyte growth factor on cell proliferation in the cellular hierarchy of the crypts of the murine small intestine. Cell Growth Differ 12:265–275PubMedGoogle Scholar
  79. Puck TT, Marcus PI (1956) Action of X-rays on mammalian cells. J Exp Med 103:653–666PubMedCrossRefGoogle Scholar
  80. Rades D, Fehlauer F, Bajrovic A, Mahlmann B, Richter E, Alberti W (2004) Serious adverse effects of amifostine during radiotherapy in head and neck cancer patients. Radiother Oncol 70:261–264PubMedCrossRefGoogle Scholar
  81. Rischin D, Peters L, Fisher R, Macann A, Denham J, Poulsen M, Jackson M, Kenny L, Penniment M, Corry J, Lamb D, McClure B (2005) Tirapazamine, cisplatin, and radiation versus fluorouracil, cisplatin, and radiation in patients with locally advanced head and neck cancer: a randomized phase II trial of the trans-tasman radiation oncology group (TROG 98.02). J Clin Oncol 23:79–87PubMedCrossRefGoogle Scholar
  82. Rischin D, Peters LJ, O’Sullivan B, Giralt J, Fisher R, Yuen K, Trotti A, Bernier J, Bourhis J, Ringash J, Henke M, Kenny L (2010) Tirapazamine, cisplatin, and radiation versus cisplatin and radiation for advanced squamous cell carcinoma of the head and neck (TROG 02.02, HeadSTART): a phase III trial of the trans-tasman radiation oncology group. J Clin Oncol 28:2989–2995PubMedCrossRefGoogle Scholar
  83. Robbins ME, Diz DI (2006) Pathogenic role of the renin-angiotensin system in modulating radiation-induced late effects. Int J Radiat Oncol Biol Phys 64:6–12PubMedCrossRefGoogle Scholar
  84. Rubin P, Johnston CJ, Williams JP, McDonald S, Finkelstein JN (1995) A perpetual cascade of cytokines postirradiation leads to pulmonary fibrosis. Int J Radiat Oncol Biol Phys 33:99–109PubMedCrossRefGoogle Scholar
  85. Saha D, Watkins L, Yin Y, Thorpe P, Story MD, Song K, Raghavan P, Timmerman R, Chen B, Minna JD, Solberg TD (2010) An orthotopic lung tumor model for image-guided microirradiation in rats. Radiat Res 174:62–71PubMedCrossRefGoogle Scholar
  86. Sasse AD, Clark LG, Sasse EC, Clark OA (2006) Amifostine reduces side effects and improves complete response rate during radiotherapy: results of a meta-analysis. Int J Radiat Oncol Biol Phys 64:784–791PubMedCrossRefGoogle Scholar
  87. Semenza GL (2007) Evaluation of HIF-1 inhibitors as anticancer agents. Drug Discov Today 12:853–859PubMedCrossRefGoogle Scholar
  88. Semenza GL, Shimoda LA, Prabhakar NR (2006) Regulation of gene expression by HIF-1. Novartis Found Symp 272:2–8 (discussion 8–14, 33–16)Google Scholar
  89. Sheldon PW, Hill SA, Foster JL, Fowler JF (1976) Radiosensitization of C3H mouse mammary tumours using fractionated doses of X rays with the drug Ro-07-0582. Br J Radiol 49:76–80Google Scholar
  90. Skov KA, MacPhail S (1994) Low concentrations of nitroimidazoles: effective radiosensitizers at low doses. Int J Radiat Oncol Biol Phys 29:87–93PubMedCrossRefGoogle Scholar
  91. Song SY, Choi W, Shin SS, Lee SW, Ahn SD, Kim JH, Je HU, Park CI, Lee JS, Choi EK (2009) Fractionated stereotactic body radiation therapy for medically inoperable stage I lung cancer adjacent to central large bronchus. Lung Cancer 66:89–93PubMedCrossRefGoogle Scholar
  92. Sprong D, Janssen HL, Vens C, Begg AC (2006) Resistance of hypoxic cells to ionizing radiation is influenced by homologous recombination status. Int J Radiat Oncol Biol Phys 64:562–572PubMedCrossRefGoogle Scholar
  93. Stone HB (1976) Metronidazole and fractionated radiotherapy of a murine tumor. Int J Radiat Oncol Biol Phys 1:1133–1137PubMedCrossRefGoogle Scholar
  94. Strandquist M (1944) Studien die kumulative wirking der roentgenstrahlen bei fraktionierung. Acta Radiol Suppl 55:1–44Google Scholar
  95. Sugie C, Shibamoto Y, Ito M, Ogino H, Suzuki H, Uto Y, Nagasawa H, Hori H (2005) Reevaluation of the radiosensitizing effects of sanazole and nimorazole in vitro and in vivo. J Radiat Res (Tokyo) 46:453–459CrossRefGoogle Scholar
  96. Sung P, Klein H (2006) Mechanism of homologous recombination: mediators and helicases take on regulatory functions. Natl Rev Mol Cell Biol 7:739–750CrossRefGoogle Scholar
  97. Thomlinson RH, Gray LH (1955) The histological structure of some human lung cancers and the possible implications for radiotherapy. Br J Cancer 9:539–549PubMedCrossRefGoogle Scholar
  98. Thompson LH, Schild D (2002) Recombinational DNA repair and human disease. Mutat Res 509:49–78PubMedCrossRefGoogle Scholar
  99. Till JE, Mc CEA (1961) A direct measurement of the radiation sensitivity of normal mouse bone marrow cells. Radiat Res 14:213–222PubMedCrossRefGoogle Scholar
  100. Timmerman RD, Story M (2006) Stereotactic body radiation therapy: a treatment in need of basic biological research. Cancer J 12:19–20PubMedCrossRefGoogle Scholar
  101. Timmerman R, McGarry R, Yiannoutsos C, Papiez L, Tudor K, DeLuca J, Ewing M, Abdulrahman R, DesRosiers C, Williams M, Fletcher J (2006) Excessive toxicity when treating central tumors in a phase II study of stereotactic body radiation therapy for medically inoperable early-stage lung cancer. J Clin Oncol 24:4833–4839PubMedCrossRefGoogle Scholar
  102. Timmerman R, Bastasch M, Saha D, Abdulrahman R, Hittson W, Story M (2007a) Optimizing dose and fractionation for stereotactic body radiation therapy. Normal tissue and tumor control effects with large dose per fraction. Front Radiat Ther Oncol 40:352–365PubMedCrossRefGoogle Scholar
  103. Timmerman RD, Kavanagh BD, Cho LC, Papiez L, Xing L (2007b) Stereotactic body radiation therapy in multiple organ sites. J Clin Oncol 25:947–952PubMedCrossRefGoogle Scholar
  104. Timmerman RD, Park C, Kavanagh BD (2007c) The North American experience with stereotactic body radiation therapy in non-small cell lung cancer. J Thorac Oncol 2:S101–S112PubMedCrossRefGoogle Scholar
  105. Timothy AR, Overgaard J, Overgaard M (1984) A phase I clinical study of Nimorazole as a hypoxic radiosensitizer. Int J Radiat Oncol Biol Phys 10:1765–1768PubMedCrossRefGoogle Scholar
  106. Vujaskovic Z, Anscher MS, Feng QF, Rabbani ZN, Amin K, Samulski TS, Dewhirst MW, Haroon ZA (2001) Radiation-induced hypoxia may perpetuate late normal tissue injury. Int J Radiat Oncol Biol Phys 50:851–855PubMedCrossRefGoogle Scholar
  107. Vujaskovic Z, Batinic-Haberle I, Rabbani ZN, Feng QF, Kang SK, Spasojevic I, Samulski TV, Fridovich I, Dewhirst MW, Anscher MS (2002) A small molecular weight catalytic metalloporphyrin antioxidant with superoxide dismutase (SOD) mimetic properties protects lungs from radiation-induced injury. Free Radic Biol Med 33:857–863PubMedCrossRefGoogle Scholar
  108. Wang JZ, Huang Z, Lo SS, Yuh WT, Mayr NA (2010) A generalized linear-quadratic model for radiosurgery, stereotactic body radiation therapy, and high-dose rate brachytherapy. Sci Transl Med 2:39ra48PubMedCrossRefGoogle Scholar
  109. Weterings E, Chen DJ (2008) The endless tale of non-homologous end-joining. Cell Res 18:114–124PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2012

Authors and Affiliations

  • Michael D. Story
    • 1
  • Chaitanya Nirodi
    • 1
  • Clinton Park
    • 2
  1. 1.Division of Molecular Radiation Biology, Department of Radiation OncologyUniversity of Texas Southwestern Medical CenterDallasUSA
  2. 2.Texas OncologyFort WorthUSA

Personalised recommendations